Table 3.
ROC curve assessment of the diagnostic utility of the top 50 AD-associated MCI biomarkers
| Top 50 values | |||
|---|---|---|---|
| MCI (n = 25) vs. | Top 50 markers |
||
| AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | |
| Age-matched controls (n = 25) | 1 | 1 | 1 |
| Early-stage PD (n = 25) | 1 | 1 | 1 |
| Mild-moderate PD (n = 25) | 1 | 1 | 1 |
| Mild-moderate AD∗ (n = 50) | 1 | 1 | 1 |
| Multiple sclerosis (n = 25) | 1 | 1 | 1 |
| Breast cancer (n = 11) | 1 | 1 | 1 |
ROC curve analyses (Testing Set subjects only) showing the diagnostic utility of the top 50 biomarkers for distinguishing AD-associated MCI subjects from age-matched controls and from the subject groups listed. Area under the curve (AUC) values at 95% confidence are listed along with values for sensitivity and specificity derived from ROC curve output data.
∗
The average of 25 MCI samples versus two Testing Sets of 25 mild-moderate AD samples each.